All Stories

  1. Coronary revascularization and sex differences in cardiovascular mortality after myocardial infarction in 12 high and middle-income European countries
  2. TRADITIONAL RISK FACTORS AND PREMATURE ACUTE CORONARY SYNDROMES IN SOUTH EASTERN EUROPE
  3. Traditional risk factors and premature acute coronary syndromes in South Eastern Europe: a multinational cohort study
  4. Abstract 18529: Early Coronary Revascularization Among "Stable" Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: The Role of Diabetes and Age
  5. Abstract 16665: Traditional Risk Factors and Acute Coronary Syndrome Free Survival
  6. Ischemic burden and cardiovascular mortality in 12 middle- and high-income European countries
  7. Age and Gender Impact on Heart Rate Variability towards Noninvasive Glucose Measurement
  8. Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
  9. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers
  10. Correction to: Relationship between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID‐19 and Preexisting Cardiovascular Disease
  11. Relationship Between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID‐19 and Preexisting Cardiovascular Disease
  12. Sex Differences in Heart Failure Following Acute Coronary Syndromes
  13. SEX DIFFERENCES AND DISPARITIES IN CARDIOVASCULAR COMPLICATIONS AND INTENSIVE CARE UNIT ADMISSION ASSOCIATED WITH COVID-19
  14. Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
  15. Sex differences and disparities in cardiovascular outcomes of COVID-19
  16. Evaluation of ongoing stability data for Zolpidem film coated tablets using statistical methods for trending analysis
  17. Abstract 11122: Sex Differences and Disparities in Cardiovascular Outcomes of Covid-19
  18. Cohort Profile: The ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
  19. COVID-19 and acute heart failure among patients with cancer
  20. Prevalence of standard modifiable cardiovascular risk factors in patients with ST segment elevation myocardial infarction and its relation with outcomes
  21. Prognostic value of brain natriuretic peptide in COVID-19 with or without acute heart failure
  22. Relation between sex and mortality after myocardial infarction in high-income and middle-income European countries
  23. Paraoxonase 1 gene polymorphisms in lipid oxidation and atherosclerosis development
  24. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
  25. Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation
  26. Antioxidative Effects of Rosuvastatin in Low-to-Moderate Cardiovascular Risk Subjects
  27. SEX DIFFERENCES IN MORTALITY AFTER MYOCARDIAL INFARCTION IN HIGH-INCOME AND MIDDLE-INCOME EUROPEAN COUNTRIES.
  28. Incremental Value of Cardiac Biomarkers in Mid-term Prognosis of Patients with Acute Coronary Syndrome
  29. Comparing Time and Frequency Domain Heart Rate Variability for Deep Learning-Based Glucose Detection
  30. THE EFFECT OF METHYLPREDNISOLONE VERSUS DEXAMETHASONE IN INCREASING THE DIABETOGENIC EFFECT OF SARS-CoV-2 INFECTION AND THE DEVELOPMENT OF A NEW-ONSET DIABETES MELLITUS
  31. Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk
  32. Left Ventricular Aneurysm with Recurrent Ventricular Tachycardia
  33. Abstract 13310: Early Percutaneous Coronary Intervention: Risks and Outcomes in Patients With Cancer
  34. Acute heart failure: a mechanism underscoring sex differences in outcomes following acute coronary syndromes
  35. Is early percutaneous coronary intervention safe in patients ACS and cancer?
  36. Distribution Analysis of Long-Term Heart Rate Variability Versus Blood Glucose
  37. Developing A Deep Learning Solution to Estimate Instantaneous Glucose Level from Heart Rate Variability
  38. Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
  39. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the Eu...
  40. Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World
  41. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia
  42. Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry
  43. Functional and structural adaptations of the coronary macro- and microvasculature to regular aerobic exercise by activation of physiological, cellular, and molecular mechanisms: ESC Working Group on Coronary Pathophysiology and Microcirculation positio...
  44. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe
  45. International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19
  46. SEX DIFFERENCES IN HEART FAILURE FOLLOWING ACUTE CORONARY SYNDROMES
  47. STATINS AND SEVERITY OF CLINICAL MANIFESTATIONS AMONG WOMEN AND MEN WITH INCIDENT CORONARY HEART DISEASE
  48. Comparison of 24 h ECG Holter Monitoring with Real-time Long-term ECG Monitoring System using ECGalert Software and Savvy Single-Lead Patch
  49. International Impact of COVID-19 on the Diagnosis of Heart Disease
  50. GENDER DIFFERENCES AND PREDICTORS OF INCRASED CORONARY CALCIUM SCORE AND MYOCARDIAL ISCHEMIA IN DIABETES TYPE 2 PATIENTS
  51. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry
  52. Correlating Short-Term Heart Rate Variability and Instantaneous Blood Glucose Measurements
  53. Heart Rate Variability of 30-minute ECG Measurements and Correlation to Glucose Levels
  54. Abstract 13648: Sex Differences in Modifiable Risk Factors and Severity of Coronary Artery Disease
  55. Added Value of Modified Anderson–Wilkins Acuteness Score in Prognostication of Patients with Acute Myocardial Infarction
  56. Novel Inflammatory Biomarkers as Additional Value to Traditional Risk-factors in Cardiovascular Risk Stratification
  57. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI
  58. Risk factors, revascularization therapies and cardiovascular mortality in countries with middle and low public health expenditure
  59. Is there a place for rosuvastatin in the Lp(a) management?
  60. Sex Differences in Modifiable Risk Factors and Severity of Coronary Artery Disease
  61. Aspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factors
  62. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on ‘coronary microvascular dysfunction in cardiovascular disease’
  63. Organization of intensive cardiac care units in Europe: Results of a multinational survey
  64. Correlating Glucose Regulation with Lipid Profile
  65. Sex-Related Differences in Heart Failure After ST-Segment Elevation Myocardial Infarction
  66. P6419Machine learning in critical care: the role of diabetes and age in acute coronary syndromes
  67. P3844Percutaneous coronary intervention in the age of frailty
  68. “DE NOVO” HEART FAILURE: A MECHANISM UNDERSCORING SEX DIFFERENCES IN OUTCOMES AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
  69. 2018 ESC/ESH Guidelines for the management of arterial hypertension
  70. Sex‐Specific Treatment Effects After Primary Percutaneous Intervention: A Study on Coronary Blood Flow and Delay to Hospital Presentation
  71. When statin alone or in combination with ezetimibe are not еnough.
  72. Myocardial Perfusion Abnormalities in Young and Premenopausal Women with Systemic Lupus Erythematosus, Detected with 99MTC MIBI Myocardial Perfusion Scintigraphy – Prevalence and Correlation with Proatherogenic Factors
  73. 2018 ESC/ESH Guidelines for the management of arterial hypertension
  74. P580Sex difference in the impact of delay to reperfusion on coronary blood flow and outcomes in ST-segment elevation myocardial infarction
  75. Adding ezetimibe to statin therapy: latest evidence and clinical implications
  76. The Impact of Glyco-Metabolic Status in Patients Treated for Acute Coronary Syndrome
  77. Perfusión tejido-músculo evaluada mediante protocolo de un día de gammagrafía reposo-dipiramidol con 99m Tc-MIBI en pacientes no diabéticos y diabéticos
  78. Tissue-muscle perfusion assessed by one day 99m Tc-MIBI rest-dipyridamol scintigraphy in non-diabetic and diabetic patients
  79. Effects of treatment with Statine on Dislipidemia in patients with diabetes.
  80. 2018 ESC Guidelines for the diagnosis and management of syncope
  81. IMPACT OF THE AGE OF FRAILTY ON OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROMES
  82. Secondary Thromboprophylaxis in Hereditary Thrombophilia
  83. Machine Learning in Critical Care: The Role of Diabetes and Age in Acute Coronary Syndromes
  84. Acute Coronary Syndrome: The Risk to Young Women
  85. P4652Myocardial infarction: process of care measures in eastern Europe: insights for complementary metrics
  86. Influence of ABCB1 C3435T Genotype on Clinical Cardiovascular Outcomes in Coronary Artery Disease Patients on Clopidogrel Treatment
  87. Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?
  88. Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a)
  89. Comparison of Early Versus Delayed Oral β Blockers in Acute Coronary Syndromes and Effect on Outcomes
  90. Are diabetes mellitus and lipoprotein(a) independently or causally associated with an increased cardiovascular risk?
  91. Diffuse Arterial Thrombosis as a First Manifestation of Occult Malignancy
  92. Antiphospholipid Syndrome - A Case Report of Pulmonary Thromboembolism, Followed with Acute Myocardial Infarction in Patient with Systemic Sclerosis
  93. Effects of rosuvastatin versus atorvastatin alone or in combination, on lipoprotein (a): a single center study.
  94. Newly Diagnosed Diabetes and Stress Glycaemia and Its’ Association with Acute Coronary Syndrome
  95. Poster Session 3: Tuesday 5 May 2015, 08:30-12:30 * Room: Poster Area
  96. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey
  97. SEX-RELATED DIFFERENCES IN ACUTE CORONARY CARE AMONG PATIENTS WITH MYOCARDIAL INFARCTION: THE ROLE OF PRE-HOSPITAL DELAY
  98. Frequencies of Single-Nucleotide Polymorphisms and Haplotypes of the SLCO1B1 Gene in Selected Populations of the Western Balkans
  99. 2014 ESC/ESA Guidelines on non-cardiac surgery
  100. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
  101. Rhabdomyolysis and Cardiomyopathy in a 20-Year-Old Patient with CPT II Deficiency
  102. Myocardial gated SPECT imaging in asymptomatic diabetic patients: clinical decision and optimal therapeutic approach
  103. Poster Session 1: Thursday 8 December 2011, 08:30-12:30 * Location: Poster Area
  104. Abstracts
  105. Occurrence and Progression of Coronary Artery Disease in Patients with Type 2 Diabetes
  106. ESTIMATION OF METABOLIC SYNDROME' COMPONENTS IN TYPE 2 DIABETIC POPULATION WITH CORONARY ARTERY DISEASE – A COMPARISON OF TWO CRITERIA
  107. Functional outcome and quality of life after coronary artery bypass surgery in patients with severe heart failure and hibernated myocardium
  108. ENDOTHELIAL DYSFUNCTION CORRELATES WITH PLASMA FIBRINOGEN AND HDL CHOLESTEROL IN TYPE 2 DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE
  109. 6.29Diagnostic value of transient ischaemic dilation (TID) and increased lung uptake as markers of severe and extensive myocardial ischaemia
  110. 1.18Combined low level treadmill-dipyridamol versus dipyridamol stress protocol in patients undergoing SPECT MPI
  111. 8.1Influence of hibernated myocardium on left ventricular remodelling in patients with severe ischaemic heart failure and coronary artery bypass surgery
  112. 6.20hs-CRP values in patients with normal myocardial perfusion
  113. Mo-P4:253 Relationship between extend of myocardial viability and post-revascularization improvement of left ventricular ejection fraction
  114. Prognosis and risk stratification of diabetic patients after coronary stenting: Impact of silent ischemia on cardiovascular events
  115. Is there a relationship between myocardial perfusion scintigraphy and carotid ultrasound findings in predictive model for coronary artery bypass patients?
  116. 40th EASD Annual Meeting of the European Association for the Study of Diabetes
  117. M.521 Implication of body mass index on long-term prognosis in patients after coronary artery bypass surgery
  118. Compact reversal rotationally shearing interferometer
  119. 1864 Assessment of myocardial perfusion after coronary stenting and implications of incomplete revascularization in multivessel coronary disease: role of gated single-photon emission computed tomography imaging
  120. Left ventricular perfusion/function differences between ischemic and dilated cardiomyopathy assessed by SPECT myocardial imaging: visual and quantitative computer analysis
  121. 1.25 Dipyridamole myoscintigraphy in patients with left bundle branch block
  122. 7.58 Myocardial viability: nitrate enhanced gated SPECT MIBI Tc99m an adequate alternation for Tl201 rest-redistribution protocol
  123. 1.38 Significance of ST-segment changes detected by ambulatory electrocardiographic monitoring and exercise treadmill stress testing in female patients who underwent myocardial perfusion scintigraphy
  124. 16.10 Evaluation of diagnostic and prognostic markers of myocardial perfusion scintigraphy and exercise treadmill stress test in patients with multivessel coronary artery disease
  125. Myocardial perfusion scintigraphic findings in patients with ischaemic cardyomiopathy versus those with preserved left ventricular function
  126. Bisoprolol reduces episodes of ventricular tachycardia and sudden cardiac death in subjects with chronic heart failure